Patent ductus arteriosus (PDA) is common in preterm infants and is associated with significant morbidities. B type natriuretic peptide (BNP) is synthesized in the ventricles secondary to volume ...

In people with no history of CV disease, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels can predict a higher risk of developing CV disease across various blood pressure and pulse pressure ...

The use of BNP/NT-proBNP levels to guide HF therapy has also been studied extensively in the last decade. A series of studies have tested whether using plasma BNP or NT-proBNP as a target to guide ...

Wanting more data on the benefits of sacubitril/valsartan vs renin angiotensin system inhibitor background therapy, investigators conducted a large randomized study among persons with heart failure ...

Please provide your email address to receive an email when new articles are posted on . Empagliflozin was safe and effective in patients with HF with reduced ejection fraction regardless of systolic ...

Please provide your email address to receive an email when new articles are posted on . NT-proBNP may predict CV death, incident HF and fatal or nonfatal CV events after acute MI. The association was ...

N-terminal pro-B-type natriuretic peptide (nt-proBNP) is an established marker of heart failure in adult cardiology. We analyzed nt-proBNP in the circulation of fetuses with increased volume load ...

In this new subanalysis of data from the Atherosclerosis Risk in the Communities study, investigators assessed the risk of incident heart failure (HF) or death by race and sex, as influenced by ...

December 14, 2009 (Basel, Switzerland) — A randomized trial of natriuretic-peptide–guided therapy for heart failure has stopped enrolling patients after an interim analysis showed that the strategy ...

RARITAN, N.J. -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, announced the CE Mark of an enhanced version of its VITROS® NT-proBNP II assay, part of Ortho's expansive cardiac ...